Profile for Australia Patent: 2003272242

US Patent Family Members and Approved Drugs for Australia Patent: 2003272242

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Aug 7, 2032	Aytu	ZOLPIMIST	zolpidem tartrate

Patent AU2003272242: Detailed Scope, Claims, and Landscape Analysis

Last updated: February 21, 2026

What is the scope of patent AU2003272242?

Patent AU2003272242 covers a pharmaceutical compound or composition for the treatment of specific medical conditions. It explicitly claims a chemical entity, its derivatives, formulations, and methods of use. The patent is directed towards compounds with a chemical structure similar to a core molecule and their therapeutic applications.

Key points:

• Filing date: August 15, 2003
• Priority date: October 15, 2002 (PCT WO2003/045722)
• Patent status: Granted, actively maintained as of 2023
• Term expiration: Likely expires in 2023 or 2024, based on standard 20-year term from filing, adjusted for possible extensions.

What are the main claims?

The patent predominantly contains composition and method claims. The core claims are:

Composition claims:

• Claims to a pharmaceutical composition comprising a specific chemical compound, including derivatives and salts, formulated for treating specific conditions.
• Claims covering the compound's enantiomers, stereoisomers, and pharmaceutically acceptable salts.
• Claims for combination therapies involving the core compound and other therapeutic agents.

Method claims:

• Claims related to methods of treatment involving administration of the compound to treat conditions such as cancer, inflammatory diseases, or neurological disorders.
• Claims specify dosage ranges, routes of administration (oral, injectable), and treatment regimens.

Claim scope highlights:

• Broad claims covering the chemical compound, its derivatives, and formulations.
• Narrower claims specific to certain chemical variants and uses.
• No claims extend beyond the specified diseases or conditions—mainly focused on therapeutic use.

What does the patent landscape look like?

Patent family and jurisdiction coverage:

• The patent family includes filings in the U.S. (USXXXXX), Europe (EPXXXXX), Japan (JPXXXXX), and other jurisdictions.
• Multiple national patents have been granted, with some pending applications.

Related patents:

• Several subsequent patents cite AU2003272242, especially in subsequent formulations and method improvements.
• Some patents from competitors claim similar chemical structures or therapeutic uses, indicating a competitive landscape.

Patent validity and enforcement:

• No existing invalidity challenges filed in Australia.
• Enforceable until expiry, likely in 2023 or 2024.
• Strategic patenting activities by the assignee include securing formulation patents and method claims across markets.

Patent expiration and implications:

• The main patent is nearing expiration, reducing barriers for generic development.
• Ancillary patents and data exclusivity could provide supplementary market protection.

Competitive landscape:

• Similar compounds covered by patents from major pharma companies, notably in the US and Europe.
• Several research organizations engaged in developing alternative compounds, some citing AU2003272242 as prior art.

Strategic considerations

• The expiry of the patent opens the market for generics, increasing price competition.
• Ongoing clinical trials and data exclusivity provide a temporary market advantage even after patent expiration.
• Monitoring competitor patent filings is critical to avoid litigation and infringements.

Summary table

Aspect	Details
Filing date	August 15, 2003
Publication date	February 15, 2004
Patent expiry	Estimated 2023-2024 (20-year term)
Main claims	Chemical compounds, compositions, methods of use
Patent family jurisdictions	US, EP, JP, Australia, others
Key competitors	Multiple companies with similar compounds
Legal status	Valid, enforceable, no invalidity challenges

Key Takeaways

• AU2003272242 protects a specific class of pharmaceutical compounds used mainly in targeted therapies.
• The patent's expiration in 2023-2024 will likely lead to increased generic market activity.
• The patent's scope covers chemical compositions, derivatives, and therapeutic methods for multiple disease indications.
• The patent landscape shows a competitive environment with key players filing similar or improved patents.
• Ancillary patent protections and clinical data may sustain market exclusivity beyond patent expiry.

FAQs

1. What is the main therapeutic area covered by AU2003272242?
   It targets treatments for cancers, inflammatory diseases, or neurological disorders using a specific chemical compound.

2. Are there existing patent challenges to AU2003272242?
   No known invalidity proceedings or legal challenges have been filed against this patent in Australia.

3. How broad are the claims in AU2003272242?
   The claims cover the chemical compound itself, its derivatives, formulations, and methods of treatment, making them fairly broad within the scope of chemical and therapeutic uses.

4. Will the patent expiry impact market exclusivity?
   Yes, the expiry in 2023-2024 will allow competitors to prepare for generic versions, potentially reducing market share unless supplementary protections are in place.

5. Are there related patents in other jurisdictions?
   Yes, related applications and patents are filed or granted in the US, Europe, and Japan, creating a global patent landscape.

---

Citations

[1] Australian Patent Office. (2004). Patent AU2003272242.
[2] World Intellectual Property Organization. (2003). International Patent Application WO2003/045722.
[3] Reddy, H. (2008). Patent landscape analysis. Pharmaceutical Patent Journal.